March 3, 2026Open Access

Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model

Key Points

Amelioration of depressive-like behaviors occurs with LHb glutamatergic pathway inhibition.
Key improvement noted in 6-OHDA-induced Parkinson's disease models.
Analysis of the glutamatergic pathway's role showcases potential therapeutic targets.
Highlights the need for further exploration of PD-related depression treatments.

Abstract

Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in 6-OHDA PD mice model. These findings offer new insights for advancing research and developing novel treatments for PD-related depression.

Inhibition of the LHb glutamatergic pathway ameliorates depressive-like behaviors in a 6-hydroxydopamine-induced Parkinson's disease mouse model

Key Points

Abstract

Cite This Study